William Blair Issues Optimistic Forecast for TWST Earnings

Twist Bioscience Co. (NASDAQ:TWST) – Investment analysts at William Blair boosted their Q1 2025 earnings estimates for shares of Twist Bioscience in a report issued on Monday, November 18th. William Blair analyst M. Larew now forecasts that the company will earn ($0.58) per share for the quarter, up from their prior estimate of ($0.72). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.56) per share. William Blair also issued estimates for Twist Bioscience’s Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.11) EPS.

A number of other analysts have also recently commented on the company. Evercore ISI upped their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday. Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Finally, Robert W. Baird increased their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $51.78.

Twist Bioscience Stock Down 0.5 %

Shares of TWST stock opened at $41.11 on Thursday. The stock has a 50-day moving average of $43.93 and a 200-day moving average of $46.15. Twist Bioscience has a one year low of $23.07 and a one year high of $60.90.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Signaturefd LLC lifted its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the second quarter worth approximately $43,000. Blue Trust Inc. lifted its position in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience during the second quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the last quarter.

Insider Activity

In other news, SVP Paula Green sold 3,310 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the completion of the sale, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This trade represents a 3.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 14,334 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. This trade represents a 2.37 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.